Exclusive Licence for a Novel Liver Function Test on Pascal
Latest announcements
Announcement summary
Exclusive Licence for a Novel Liver Function Test on Pascal
Atomo signs an exclusive global licensing agreement for a novel liver function test assay, supporting commercialisation of a rapid test for the immediate detection of liver injury.
Delivered on our proven Pascal cassette at the point-of-care and in the home, the test enables early identification of liver inflammation of any cause, giving the test commercial utility across a broad range of clinical applications.
The initial focus is monitoring for drug-induced liver injury (DILI) where rapid elevations in ALT require an urgent clinical response, with Atomo previously disclosed fulfilling an order from Burnet for 20,000 Pascal cassettes to support supply of finished tests to a multinational pharmaceutical company to enable real-time monitoring of DILI in a US drug trial.
Ask a question
Your question will be sent privately to Atomo Diagnostics. The company may choose to make this question public.
Investor Q&As
Start the conversation
Ask Atomo Diagnostics a question about this announcement.